Taken together, our findings proved that BRD7 functions as a tumor suppressor at least partially by inhibiting enhancer activity and the expression of BIRC2 in NPC, and targeting the BRD7/BIRC2 axis might provide a potential strategy for the diagnosis and treatment of NPC. Here, BIRC2 is linked to nasopharyngeal carcinoma.